1. Home
  2. RHI vs ACAD Comparison

RHI vs ACAD Comparison

Compare RHI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Robert Half Inc.

RHI

Robert Half Inc.

HOLD

Current Price

$42.49

Market Cap

4.5B

ML Signal

HOLD

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$27.94

Market Cap

4.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RHI
ACAD
Founded
1948
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
4.3B
IPO Year
1994
2000

Fundamental Metrics

Financial Performance
Metric
RHI
ACAD
Price
$42.49
$27.94
Analyst Decision
Hold
Buy
Analyst Count
7
22
Target Price
$30.33
$30.55
AVG Volume (30 Days)
1.6M
1.4M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
8.68%
N/A
EPS Growth
N/A
69.12
EPS
0.40
0.20
Revenue
$5,378,506,000.00
$726,437,000.00
Revenue This Year
$1.27
$18.80
Revenue Next Year
$5.95
$11.70
P/E Ratio
$107.00
$141.35
Revenue Growth
N/A
40.45
52 Week Low
$21.83
$19.69
52 Week High
$46.70
$30.96

Technical Indicators

Market Signals
Indicator
RHI
ACAD
Relative Strength Index (RSI) 51.96 48.65
Support Level $26.19 $27.90
Resistance Level $46.70 $30.96
Average True Range (ATR) 1.44 0.84
MACD -0.44 -0.29
Stochastic Oscillator 13.72 2.18

Price Performance

Historical Comparison
RHI
ACAD

About RHI Robert Half Inc.

Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: